ERT, HRT, raloxifine, calcitonin, or bisphosphonates for osteoporosis.
Curtiss
Frederic R
FR
D000368:Aged; D002116:Calcitonin / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000191:economics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004965:Estrogen Antagonists / Q000191:economics / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000191:economics; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000191:economics*; D006801:Humans; D018803:Models, Economic; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control; D017698:Postmenopause; D011372:Progestins / Q000191:economics / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride / Q000191:economics / Q000627:therapeutic use*; D012307:Risk Factors
D004164:Diphosphonates; D004965:Estrogen Antagonists; D011372:Progestins; D020849:Raloxifene Hydrochloride; D002116:Calcitonin